|
|
|
| Treatment of thymus malignant melanoma with PD-1 inhibitors：a case report and review of the literature |
| SONG Yipeng1 SUN Sanyuan1 HAN Liang1 LIU Wei1 HUANG Liu2#br# |
1.Department of Oncology, Xuzhou Central Hospital, Jiangsu Province, Xuzhou 221000, China;
2.Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Province, Wuhan 430000, China |
|
|
|
Abstract Thymic malignant melanoma is a rare ectopic thymic tumor with high invasivity. For patients with advanced thymic tumor that cannot be surgically resected, radiotherapy and chemotherapy are the traditional treatment methods, but the effect is poor. Recently, immune checkpoint inhibitors have shown good anti-tumor effects. According to previous reports, the use of immune checkpoint inhibitors in the treatment of thymic tumors and thymic carcinoma causes a high proportion of serious immune-related adverse reactions. There has been no report of immune checkpoint inhibitors in the treatment of thymic malignant melanoma. This case on October 4, 2021 in the Xuzhou Central Hospital, Jiangsu Province, by biopsy and gene detects the definite diagnosis of primary melanoma of the thymus gland malignant, after six cycles of Tririplizumab treatment, chest tightness and wheezing symptoms were relieved, and the tumor was reduced, the treatment effect was evaluated as partial remission, and the patient is still under treatment and follow-up. This article through to the patient’s diagnosis, treatment and follow-up process, review and summarize the related literatures, the thymus gland malignant melanoma is relatively rare, need to identify with other thymic tumor pathologically, using immune checkpoint inhibitors in thymus treatment in patients with malignant melanoma may show a good effect, immune related adverse reaction probability than other thymic tumor is low, it can provide treatment ideas for similar cases in the future.
|
|
|
|
|
|
[1] Girard N，Ruffini E，Marx A，et al. Thymic epithelial tumours：ESMO Clinical Practice Guidelines for diagnosis，treatment and follow-up [J]. Ann Oncol，2015，26（5）：40- 55.
[2] Krishnan M，Ganti AK. The role of targeted therapy in thymic carcinoma [J]. Oncol Pharm Pract，2019，25（7）：1712-1718.
[3] Marx A，Chan JK，Coindre JM，et al. The 2015 World Health Organization Classification of Tumors of the Thymus：Continuity and Changes [J]. Thorac Oncol，2015，10（10）：1383- 1395.
[4] Chen YL，Zhao J，Jia R，et al. Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab：a case report and literature review [J]. Zhonghua Jie He He Hu Xi Za Zhi，2017，40（10）：736-743.
[5] Pujani M，Hassan MJ，Jetley S，et al. Malignant Melanoma Presenting as a Mediastinal Malignant Melanoma Presenting as a Mediastinal Unknown Primary Origin? [J]. Turk Patoloji Derg，2017，33（2）：168-170.
[6] Shi Y，Bing Z，Xu X，et al. Primary pulmonary malignant melanoma：Case report and literature review [J]. Thorac Cancer，2018，9（9）：1185-1189.
[7] Png J，Han F，Yang T，et al. Primary malignant melanoma of the lung：A case report and literature review [J/OL]. Medicine （Baltimore），2017，96（46）：e8772. https：//doi.org/10.1097/ MD. 0000000000008772.
[8] Maeda R，Isowa N，Onuma H，et al. Primary malignant melanoma of the lung with rapid progression [J]. Gen Thorac Cardiovasc Surg，2009，57（12）：671-674.
[9] Minca EC，Al-Rohil RN，Wang M，et al. Comparison between melanoma gene expression score and fluorescence in situ hybridization for the classification of melanocytic lesions [J]. Mod Pathol，2016，29（8）：832-843.
[10] Gerami P，Alsobrook JP 2nd，Palmer TJ，et al. Development of a novel noninvasive adhesive patch test for the evaluation of pigmented lesions of the skin [J]. Am Acad Dermatol，2014，71（2）：237-244.
[11] Ji AL，Bichakjian CK，Swetter SM. Molecular Profiling in Cutaneous Melanoma [J]. Natl Compr Canc Netw，2016，14（4）：475-480.
[12] Vergier B，Prochazkova-Carlotti M，de la Fouchardière A，et al. Fluorescence in situ hybridization，a diagnostic aid in ambiguous melanocytic tumors：European study of 113 cases [J]. Mod Pathol，2011，24（5）：613-623.
[13] Ponti G，Ruini C，Massi D，et al. Fluorescence in-situ hybridization and dermoscopy in the assessment of controversial melanocytic tumors [J]. Melanoma Res，2013，23（6）：474-480.
[14] Weissinger SE，Frick M，M?觟ller P，et al. Performance Testing of RREB1，MYB，and CCND1 Fluorescence In Situ Hybridization in Spindle-Cell and Desmoplastic Melanoma Argues for a Two-Step Test Algorithm [J]. Int J Surg Pathol，2017，25（2）：148-157.
[15] Zucali PA，De Vincenzo F，Perrino M，et al. Systemic treatments for thymic tumors：a narrative review [J/OL]. Mediastinum，2021，5：24. https：//doi.org/10.21037/med-21-11.
[16] Arun R，Christopher H，Andrew M，et al. OA18.03 Safety and Clinical Activity of Avelumab （MSB0010718C； Anti-PD-L1） in Patients with Advanced Thymic Epithelial Tumors （TETs）[J]. J Thorac Oncol，2017，12（1）：314-315.
[17] Giaccone G，Kim C，Thompson J，et al. Pembrolizumab in patients with thymic carcinoma：a single-arm，single-centre，phase 2 study [J]. Lancet Oncol，2018，19（3）：347-355.
[18] Tarrio ML，Grabie N，Bu DX，et al. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis [J]. J Immunol，2012，188（10）：4876-4884.
[19] Michot JM，Bigenwald C，Champiat S，et al. Immune-related adverse events with immune checkpoint blockade：a comprehensive review [J]. Eur J Cancer，2016，54：139-148.
[20] Board R，Smittenaar R，Lawton S，et al. Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018 [J]. Int J Cancer，2021，148（4）：868-868. |
|
|
|
